Scientific Journals and Yearbooks Published at SAS

Volume 71, 2024, No. 5

• Demkova, L. - Matuskova, M. - Gercakova, K. - Kozovska, Z. - Smolkova, B. - Kucerova, L.: The impact of c-Met inhibition on molecular features and metastatic potential of melanoma cells. (p. 417)
• Zhang, X. - Li, J. - Zhang, Q.: EIF4A3-induced circle RNA_ 0001860 promotes growth, invasion, and immune evasion of gastric cancer cells through the miR-618/HMGA2 axis. (p. 428)
• Guo, D. - Ma, C. - Gu, J. - Zhai, X. - Chen, X. - Ju, G. - Chu, C. - Zhan, X. - Wang, T. - Tan, M. - Xu, D.: Exploring the role of eIF3m in prostate cancer: regulation of c-Myc signaling pathway and therapeutic implications. (p. 442)
• Li, J. - Cheng, X. - Huang, D. - Cui, R.: Six2 regulates the malignant progression and 5-FU resistance of hepatocellular carcinoma through the PI3K/AKT/mTOR pathway and DNMT1/E-cadherin methylation mechanism. (p. 451)
• Huang, Z. - Zhang, W. - Huang, K. - Feng, J.: Determination of serum vitamin D in patients with renal, bladder, and prostate cancer by ultra-performance liquid chromatography-tandem mass spectrometry. (p. 463)
• Shin, E. - Koo, J. S.: Protein level of epithelial membrane protein (EMP) 1, EMP 2, and EMP 3 in carcinoma of unknown primary. (p. 473)
• Li, X. - Wu, D. - Tang, J. - Wu, Y.: Albumin bound-paclitaxel combined with anlotinib and immunotherapy in the second-line treatment of ES-SCLC: a retrospective cohort study. (p. 482)
• Zhang, F. - Cui, Q. - Du, H. - Lv, X. - Hou, T. - Chen, Y. - Chen, J. - Liu, J. - Yan, J. - Liu, Y.: Comparative investigation among fluorescence in situ hybridization, DNA- and RNA-sequencing on detecting MYC, BCL2, and BCL6 rearrangements in high-grade B-cell lymphomas. (p. 490)
• Ondrušová, M. - Suchanský, M. - Vándor Svidová, S. - Chowaniecová, G. - Mrinakova, B. - Sekerešová, M. - Juskanič, D. - Ondrus, D. - Šenitko, M.: The real-world comparison of non-small cell lung cancer survival outcomes depending on immunotherapy treatment and PD-L1 expression level. (p. 498)
• Ying, X. - Shi, Z. - Shao, R. - You, G. - Song, Z.: Correction: Efficacy and safety analysis of anlotinib in combination with immune checkpoint inhibitors for second-line and subsequent extensive-stage small-cell lung cancer. (p. 509)